Specific considerations for the management of primary biliary cholangitis : are the drug treatment options good enough?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Expert opinion on pharmacotherapy - 22(2021), 15 vom: 14. Okt., Seite 1949-1953 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wetten, Aaron [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.10.2021 Date Revised 10.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14656566.2021.1940135 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326694439 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326694439 | ||
| 003 | DE-627 | ||
| 005 | 20231225195140.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14656566.2021.1940135 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1088.xml |
| 035 | |a (DE-627)NLM326694439 | ||
| 035 | |a (NLM)34121570 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wetten, Aaron |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Specific considerations for the management of primary biliary cholangitis |b are the drug treatment options good enough? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.10.2021 | ||
| 500 | |a Date Revised 10.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Bezafibrate | |
| 650 | 4 | |a Fatigue | |
| 650 | 4 | |a Obeticholic acid | |
| 650 | 4 | |a Primary Biliary Cholangitis | |
| 650 | 4 | |a Pruritus | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a Ursodeoxycholic acid | |
| 650 | 4 | |a pharmacotherapy | |
| 650 | 7 | |a Cholagogues and Choleretics |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 650 | 7 | |a Chenodeoxycholic Acid |2 NLM | |
| 650 | 7 | |a 0GEI24LG0J |2 NLM | |
| 650 | 7 | |a Ursodeoxycholic Acid |2 NLM | |
| 650 | 7 | |a 724L30Y2QR |2 NLM | |
| 700 | 1 | |a Jones, David Emrys Jeffreys |e verfasserin |4 aut | |
| 700 | 1 | |a Dyson, Jessica Katharine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on pharmacotherapy |d 1999 |g 22(2021), 15 vom: 14. Okt., Seite 1949-1953 |w (DE-627)NLM111602130 |x 1744-7666 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:15 |g day:14 |g month:10 |g pages:1949-1953 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14656566.2021.1940135 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 15 |b 14 |c 10 |h 1949-1953 | ||